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 Abstract 
Objective 
Malignant Bowel Obstruction (MBO) is a complication of advanced malignancy and is 
associated with a short prognosis.  MBO can infrequently be reversed by surgery or 
stenting.  The focus of treatment is usually symptomatic management, of which 
percutaneous venting gastrostomy/gastrojejunostomy (PVG) is one consideration.  There is 
little data considering the impact of PVG on quality of life; we therefore aimed to explore 
this.  
Methods 
We identified patients with PVG inserted for MBO and those who consented to participate 
were interviewed.  The interviews were audio-recorded, transcribed and analysed using 
Framework.  Alongside patient interviews, a data collection tool was designed and utilised 
to record patient demographics and medical information, enabling us to contextualise 
individual patients’ experiences. 
 Results 
11 patients were interviewed and 10 patients’ data was analysed (1 patient withdrew).  No 
patients regretted having a PVG and many benefitted symptomatically and psychosocially.  
Challenges encountered included practical issues, pain and PVG tube complications.   
Conclusions 
The analysis provided a detailed insight into the impact of PVG insertion and demonstrated 
that each patients’ experience is shaped by a complex interplay of individual factors, 
thereby highlighting the need to improve referral criteria and individualise patient 
selection.  Other service improvements include enhancing information provision for 
patients and training for Healthcare Professionals’, thus aiming to mitigate the challenges 
experienced.  Our study is the first in-depth exploration of patients’ experiences of PVG at a 
tertiary cancer centre.  Ensuring that the insights from this study are fed back to guide 
future service provision is critical in enhancing future patient experiences. 
 
 
 
 
 
 
 
 Introduction 
Malignant Bowel Obstruction (MBO) affects around 3-15% of patients with advanced 
cancer globally.  The incidence is higher in certain cancers; up to 50% in ovarian carcinoma 
and up to 28% in colorectal carcinoma.  MBO can be mechanical or functional, but is often 
both.  Life expectancy is generally short for patients who develop this complication, with a 
median survival of 10 weeks [1-3]. 
Management options for MBO can be divided into reversal of the obstruction or 
symptomatic control.  Reversal of the obstruction encompasses surgery or endoluminal 
stenting.  In selected patients, with a single site mechanical obstruction, surgery is likely to 
be beneficial [4-5], yet this excludes the majority of patients.  30-day surgical mortality can 
reach up to 40%, with complication rates up to 90% [4].  Endoluminal stenting has a role in 
selected patients; a gastroduodenal stent may be feasible for a single obstruction at the 
gastric outlet or proximal small bowel, and a colonic stent for a focal colo-rectal 
obstruction, providing there is a sufficient margin from the anus [5].  If reversal of the 
obstruction is not feasible patients are managed by optimising their symptoms. 
Symptom control can be subdivided into medical interventions and insertion of a 
percutaneous venting gastrostomy/gastrojejunostomy (PVG).  Medical interventions may 
include keeping the patient nil by mouth (NBM), decompressing the stomach and bowel 
with a nasogastric tube (NGT) and an intravenous infusion (IVI); (the ‘drip and suck’ 
method), as well as parenteral medications for symptom control.  Generally, an NGT is only 
justified short-term due to the complications of prolonged use [6], although in a minority of 
cases they may remain in situ for weeks/months. 
In the tertiary cancer centre where we conducted the study the interventional radiologists 
(IR) perceive a role for PVG when parenteral medications achieve suboptimal symptom 
control, and ideally following a successful trial of NGT decompression [7].  An IR assesses 
patients referred for PVG and suitable patients wanting to proceed sign a written consent 
form.  A patient information pack is available, containing a summary of general pre-PVG 
information (including ‘what is a venting gastrostomy tube’, ‘why do I need it’, ‘how can I 
control my symptoms’ and dietary advice), followed by detailed post-PVG care information.  
On discharge a PVG specific discharge letter is completed alongside the standard hospital 
discharge letter. 
Improving our understanding of the management options is critical for those treating these 
patients.  Published evidence on PVG has largely focused on feasibility, success rates, 
symptomatic relief, complications and survival.  Research has demonstrated symptomatic 
relief rates of over 90% [8-11] and restoration of some diet in over 90% of cases [8-10].  
Patients’ experiences of PVG insertion and the impact on their quality of life (QoL) remains 
unclear.  These factors need to be examined to enable clinicians and patients to make more 
informed decisions regarding MBO management and patient selection for PVG.  
 This study aimed to explore individual patient experiences of PVG alongside information 
regarding their treatment journey.  We aim to feedback to the PVG service providers and 
guide service development to enable more informed decision making, thereby enhancing 
patient experience.   
 
Methods 
This study was undertaken as part of a wider study with the ultimate aim to devise a PVG 
registry within the tertiary hospital.  Prior to this the team felt it would be beneficial to 
further explore patient experiences with PVG.  Our proposal was submitted to the 
hospital’s Research and Development Department, who decided that this would best be 
defined as a service evaluation project (reference number CE15/1486). 
Qualitative interviews were used to facilitate an in-depth exploration of patient experiences 
of PVG.  The interviews enabled patients to verbalise their first-hand experiences and to 
guide the areas of discussion relevant to their particular ‘journey’.  Pertinent information 
from the patient’s medical notes was collected to enable contextualisation of responses.  
Both sets of results were blended together providing a more informative analysis.  
 Patients had to fulfil all of the inclusion criteria in order to be eligible to participate: 
• Adults (≥18 years of age), and 
• Diagnosis of MBO, and 
• Had already undergone (retrospective) or were due to and subsequently did undergo 
(prospective) PVG. 
Recruitment 
The study had a six-month recruitment window (January 2016 to July 2016), which was 
predetermined to coincide with the study block of the interviewers.  We approached those 
that had a PVG inserted previously and were still alive (retrospective), alongside patients 
that had a PVG inserted during the study period (prospective).  This maximised our sample 
size and gathered longer and shorter-term experiences.  Patients were screened against the 
inclusion criteria and eligible patients were approached by an interviewer who outlined the 
study.  This was done via telephone, when they attended the interventional radiology 
department for review, or during their inpatient admission. 
Demographic and medical information was gathered using a pre-generated collection tool 
(appendix A) for screening and contextual background information. 
Consent 
Following a discussion with an interviewer, patients interested in participating were 
provided with a study information leaflet and were given as much time as required to 
consider this.  Those that decided to participate then provided written consent.  Patient 3 
 wished to participate in the study, however due to fatigue he asked his wife to speak on his 
behalf, whilst he was also present.  In this case his wife signed the consent form. 
Interviews 
The semi-structured interview guide (appendix B) was developed by the wider multi-
disciplinary project team; including IRs, palliative care clinicians and a qualitative 
researcher.  It was devised to address the study objectives and was finalised following team 
discussions after each iteration.  Interviews were conducted by two members of the study 
team (junior doctors), and patients were informed that they were not acting in their 
healthcare professional capacity.  Both received training and supervision from an 
experienced qualitative researcher.  The duration of the interviews was patient led, 
typically lasting around 60 minutes.  
We aimed to interview patients identified prospectively at least one-week post-PVG 
insertion.  All interviews were audio-recorded and transcribed verbatim.  Interviews were 
face-to-face and occurred in hospital wards or the patients’ homes.  If the initial interview 
was conducted prior to one-week post-PVG insertion we aimed to re-interview the patient.  
Follow-up interviews, where applicable, were conducted by telephone, audio-recorded and 
transcribed verbatim.   
Analysis 
The interview data was analysed using Framework [12], a systematic, five-stage matrix-
based system that facilitates analysis both by theme and by case [12-16].  While less 
suitable for in-depth heavily theoretical research, the Framework method is recognised for 
its suitability for applied studies such as this and is valued for its transparency and clarity 
[17].  The five stages included familiarisation with the data from the interviews, inductive 
development of a framework, generation of an index for themes and subthemes 
(developed by interrogating data categories through comparison between and within 
cases), data synthesis and interpretation.  Multidisciplinary team (MDT) workshops were 
held for discussion of emerging themes and interpretations.  These were led by a senior 
qualitative researcher with a social science background. 
The demographic and medical information gathered using our data collection tool 
(appendix A) was combined with this data to help contextualise and interrogate the data as 
part of our analysis.  
 
 
 
 
 
 Results 
We will first report patient demographics and pre-PVG MBO management.  Then we will 
discuss the themes which emerged from the interviews under the following headings: 
overall views, positive experiences and challenges encountered with PVG.  Finally, we will 
offer suggestions for future service improvement.  
Demographics 
11/15 (73%) eligible patients were recruited to our study.  Of the 4 (27%) patients who 
were not recruited; 2/4 (50%) were uncontactable, 1/4 (25%) declined and 1/4 (25%) was 
judged inappropriate to approach as the patient was felt to be in the last hours of life.  12 
interviews were conducted; 11 face-to-face initial interviews and 1 telephone re-interview.  
9/11 (82%) of the face-to-face interviews were conducted in hospital and 2/11 (18%) were 
conducted in patients’ homes.  1/11 patients (Patient 5) withdrew from the study, leaving 
10 patients’ data for analysis (Table 1). 
The median survival post-PVG was 92 days, with a range of 10 days to 1,837 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
TABLE 1: PATIENT CHARACTERISTICS 
    
Patient Age (Years) Sex Cancer Diagnosis Episode of MBO Referrer PN Pre-PVG Recruited 
1 36 Female Ovarian 3 
 
Supportive Care Team Yes Prospectively 
        
2 72 Female Ovarian 4 Oncologist Yes Retrospectively 
        
3 79 Male Colorectal 1 Oncologist No: inappropriate Prospectively 
        
4 73 Female Endometrial 3 Oncologist Yes Retrospectively 
        
6 67 Female Ovarian 1 Oncologist No: patient chose BSC Prospectively 
        
7 77 Female Neuroendocrine: small bowel 3 Oncologist Yes Retrospectively 
        
8 60 Female Peritoneal 1 Oncologist No: patient chose BSC Prospectively 
        
9 72 Female Ovarian 1 Oncologist Yes Prospectively 
        
10 59 Female Appendiceal 1 Surgeon Yes Prospectively 
        
11 56 Female Appendiceal 4 External: IFU Team Yes Prospectively 
         
BSC = Best Supportive Care; IFU = Intestinal Failure Unit; MBO = Malignant Bowel Obstruction; PN = Parenteral Nutrition; PVG = 
Percutaneous Venting Gastrostomy/Gastrojejunostomy.  
 Pre-PVG MBO management  
Patients experienced a range of management options during their MBO course (Table 2).  
Attempts were made to reverse previous episodes of MBO; with 2/10 (20%) patients 
undergoing surgery for at least one episode of their MBO. 
With regards to medical interventions, all of the patients had experienced at least one NGT 
insertion during an episode of MBO, with 9/10 (90%) patients having an NGT inserted 
during their current episode.  The patient with no NGT in situ during their current episode 
declined because she found it unbearable.  7/10 (70%) patients had a syringe pump during 
their current episode of MBO.  A variety of regular and as required medications were 
prescribed, and varying doses of the same drug were prescribed.  The antiemetic drug 
doses in patients’ 2, 8 and 9 syringe pumps are noted to be particularly low.  Additionally, 
four patients (2, 4, 6 and 9) syringe pumps contained a single antiemetic. 
9/10 (90%) of patients received the written information pack entitled ‘Venting Gastrostomy 
Information Pack.’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLE 2: SUMMARY OF PATIENTS' JOURNEYS 
 
  Management of Previous Episodes of MBO Management of Current Episode of MBO   
 
Patient Previous Oncological Treatment Prior to Developing MBO Medical Surgical/Stent? CSCI? Medical/Surgical/Stent? NGT? Other PVG insertion 
to Interview 
(Days) 
Post-PVG 
Survival 
(Days) 
1 TAH, BSO & omentectomy  
6 lines of chemotherapy 
1st: Conservative 
2nd: Conservative 
No Yes:  
Pump 1: Octreotide 600micrograms/24hrs 
Pump 2: Levomepromazine 18.75mg/24hrs, 
Diamorphine 100mg/24hrs &  
Hyoscine Butylbromide 80mg/24hrs 
3rd: No, but IR raised the 
possibility that a stent may be 
required in addition to a PVG due 
to GOO as well as distal SBO 
Yes Granisetron Patch 3.1mg/24hrs 
every 5 days 
1st: 2  
2nd: 43 
98 
2 Laparotomy, BSO & omentectomy  
1 line of chemotherapy 
1st: Switched to 2nd line 
chemotherapy 
2nd: Switched to 3rd line 
chemotherapy 
3rd: Switched to 4th line 
chemotherapy 
No Yes: Octreotide 200micrograms/24hrs 4th: Trialled 5th line 
chemotherapy  
Yes PRNs: Hyoscine Butylbromide, 
Cyclizine & Levomepromazine 
27 59 
3 Defunctioning stoma  
Radical cystoprostatectomy, sigmoid colectomy & urostomy 
Partial hepatectomy 
Palliative radiotherapy 
3 lines of chemotherapy 
N/A N/A No 
 
Yes PRNs: Cyclizine, Ondansetron & 
Paracetamol 
5 10 
4 TAH & BSO 
EBRT 
Total pelvic exenteration with mid-colostomy & ileal conduit 
formation 
2 lines of chemotherapy 
1st: Conservative  
2nd: Conservative 
No Yes: Cyclizine 150mg/24hrs &  
Oxycodone 30mg/24hrs 
 
Yes   70 95 
6 3 lines of chemotherapy N/A N/A Yes: Cyclizine 150mg/24hrs  
 
Yes   1st: 4  
2nd: cancelled 
(died) 
27 
7 None 
 
Yes: 1st: initial presentation 
of cancer was with MBO: 
laparotomy and small bowel 
resection 
2nd: right hemicolectomy 
No 
 
Yes   1095 1837 
8 BSO & omentectomy 
3 lines of chemotherapy 
N/A N/A Yes: Haloperidol 1.25mg/24hrs, 
Hyoscine Butylbromide 20mg/24hrs & 
Morphine 10mg/24hrs 
 
Yes 
 
7 13 
9 TAH, BSO & omentectomy 
2 lines of chemotherapy 
N/A  N/A Yes: Octreotide 300micrograms/24hrs 1st: Trialled 2nd line 
chemotherapy  
Yes PRNs: Cyclizine & 
Levomepromazine 
6 91 
10 Right hemicolectomy and small bowel resection 
1 line of chemotherapy 
N/A N/A No 
 
Yes PRNs: Paracetamol, Oxycodone, 
Cyclizine & Ondansetron 
8 152 
11 Tumour resection 
Debulking surgery 
3 lines of chemotherapy 
1st: switched to 4th line 
chemotherapy 
3rd: Conservative 
Yes: 2nd: resection & 
ileostomy formation 
Yes: Levomepromazine 25mg/24hrs & 
Cyclizine 150mg/24hrs 
 
No* PRNs: Oxycodone, 
Prochlorperazine & Paracetamol 
8 93 
BSO = Bilateral Salpingo-Oophorectomy; CSCI = Continuous Subcutaneous Infusion; EBRT = External Beam Radiotherapy; GOO = Gastric Outlet Obstruction; IR = Interventional Radiologist; MBO = Malignant Bowel Obstruction; N/A = Not Applicable; NGT = Nasogastric Tube; PRNs =  As Required; PVG = 
Percutaneous Venting Gastrostomy/Gastrojejunostomy; SBO = Small Bowel Obstruction; TAH = Total Abdominal Hysterectomy. 
*Patient previously had NGTs inserted with symptomatic benefit, but declined a NGT during this episode. 
NB (1)  Under column 'Management of Previous Episodes of MBO', N/A is used to indicate the fact the patient has not had a previous episode of MBO. (2) The column 'PVG insertion to interview' refers to the date of original PVG insertion (in cases where re-insertion was necessary). 
 Patients’ overall PVG experience 
All patients stated that they did not regret having a PVG inserted and all 
patients reported that they would recommend another patient in a similar 
position to consider PVG insertion.  We explored the reasoning behind this. 
One reason was survival, with several patients being glad they had undergone 
PVG due to their perception that it had increased their survival.  Some felt 
there was no alternative to PVG, with others believing that PVG insertion was 
optimal because it came recommended by a medical professional.   
“Certainly yes, I mean what’s the alternative…you just have to go with 
what the doctors recommend I think.” 
(Patient 2, female, age 72, 4 weeks post-PVG) 
Patients’ positive PVG experiences 
Patients discussed two main positive impacts of PVG on their life; amelioration 
of symptoms and enabling their NGTs to be removed [for all but 1/10 (10%); 
Patient 1].  
All reported that their nausea and vomiting either reduced or subsided 
completely post-PVG insertion.  Other improvements included reductions in 
pain and abdominal distention. 
“Well they explained that it would be helpful for the sickness…stopping 
the sickness, which it did.  I was so grateful for that because it was just 
projectile all the time.” 
(Patient 7, female, age 77, 3 years post-PVG) 
Removal of their NGTs was seen as a benefit post-PVG insertion; improving 
their comfort, body image and dignity.  Body image was greatly improved 
following NGT removal for many who described feeling self-conscious due to 
the visibility of their NGT.  Patient 3 and his Spouse referred to his NGT as a 
‘trunk’. In contrast to their NGT, many patients were pleased that their PVG 
could be hidden, resulting in increased self-assurance and facilitating them 
going out in public and socialising. 
 
  “I hated that up my nose because it was so uncomfortable.  It hurt 
me…it was horrible and uncomfortable in my throat, but this (referring 
to her PVG tube) isn’t uncomfortable.” 
(Patient 2, female, age 72, 4 weeks post-PVG) 
Challenges with PVG 
Despite the positive experiences, there were some challenges raised by 
patients regarding their PVG.  These include practical issues, psychosocial 
issues, pain and PVG tube complications. 
One practical difficulty related to tube anatomy; patients were required to 
remove the stopper at the end of the tube to drain stomach contents.  Some 
struggled with this, especially those with reduced manual dexterity and those 
with decreased functional status.  Others felt their PVG impeded their mobility; 
particularly patients with multiple devices/attachments; such as Parenteral 
Nutrition (PN), stomas and syringe pumps.  
(are you able to walk up and down the stairs?) 
“…not when carrying my bags (referring to her PVG, PN and syringe 
pump), but X (partner) carries those either behind or in front of me.” 
 (Patient 9, female, age 72, 1-week post-PVG, at home) 
The PVG affected social confidence.  One patient felt conscious of an odour 
perceived to be coming from her PVG, described as ‘sewage’.  This caused 
anxiety due to her concern that others could smell this. 
“You can smell it though, even if it’s not leaking.  I feel like…it smells like 
sewage, it’s not faecal, it’s worse than that, it’s a sewage smell and I feel 
like I can smell it all the time and anyone who is anywhere near me can 
smell it.  It is making me quite paranoid, I am constantly asking my 
husband if he can smell it…I don’t get embarrassed too easily, but I do 
find that quite difficult to deal with.” 
(Patient 1, female, age 36, 6 weeks post-PVG) 
Some felt the pain post-procedure was more severe or lasted longer than 
anticipated.  Some patients developed an infection and were treated with 
antibiotics.  Furthermore, some patients experienced leakage of gastric 
contents due to their tube bypassing, causing discomfort.  For one patient, the 
volume resulted in their bedsheets being changed several times per day.  
 Despite interventions to minimise this leakage, this patient’s skin became 
necrotic. 
“My husband has been in a lot of discomfort, it has been leaking all the 
time, he’s being changed numerous times a day, the beds have to be 
changed and now his skin is all sore.” 
(Patient 3, male, age 79, 1-week post-PVG) 
Other complications included tubes dislodging, with one patient’s tube falling 
out multiple times.  All tubes were initially confirmed as correctly sited, yet 
several tubes were subsequently found to be displaced.  Imaging revealed that 
two patients’ tubes were in their oesophagus. 
Identified areas for service improvement 
All of the patients discussed ways in which they felt their experience of PVG 
could be enhanced; largely divided into the provision of patient information 
and HCPs’ education and training.  
Information provision encompassed; PVG specific information, the timing, 
quantity and consistency of information, as well as follow-up information. 
For many of the patients, a PVG was initially raised by their treating team (as 
seen in Table 1).  During this initial discussion many felt they would have 
benefitted from more information; why a PVG was being considered, what 
they could expect from a PVG and alternative options.  Many felt they made 
the decision to proceed with a PVG without this, with the first in-depth 
conversation being during the written consent process with an IR.  Some felt 
reassured with this information provided by the individual that was to perform 
the procedure and felt this instilled trust in that clinician.  Others felt that 
receiving detailed information at this point was too late.  
 “…when I got down to radiology, Dr X (Consultant IR) came and 
explained it all to me and I was even more anxious then because I sort of 
then understood what was happening…” 
(Patient 10, female, age 59, 1-week post-PVG, not given any written 
information pre-PVG) 
The hospital provided a written resource on PVG which was given to patients 
at different times; some received this before their procedure, whereas others 
received it after PVG insertion.  As it is a detailed document the patients felt it 
 should be provided a reasonable amount of time beforehand to enable 
digestion of the information.  One suggested improvement was to include 
patient stories containing positive and negative experiences. 
Overlapping somewhat with information provision is HCPs’ education and 
training.  This includes HCPs ensuring patients are adequately informed prior 
to PVG insertion to facilitate realistic patient expectations, in addition to staff 
being competent and confident in post-PVG care, both in the hospital and 
community.  
Some patients had unrealistic expectations, such as; their PVG would 
completely resolve their symptoms, guarantee resumption of their usual diet 
and/or prolong their life expectancy.  One patient was given conflicting 
information regarding the care of her PVG.  One patient did not feel confident 
in the way that the HCPs’ cared for her PVG tube and some felt that they were 
not supported by HCPs to facilitate their autonomy in caring for their PVG.  
 (Referring to ward nurses): 
“…one nurse who was giving it a clean said, you don’t rotate this 
one…that other nurse, she said something about I’ll rotate it and I said 
oh well I’ve been told not to rotate mine.” 
(Patient 6, female, age 67, 1-week post-PVG) 
 
Discussion 
This study explored patients’ experiences of PVG in the management of MBO.  
This was achieved through interviews with patients post PVG insertion 
alongside data collection regarding their patient journey.  All patients felt PVG 
had enhanced their quality of life; symptomatically, psychosocially and through 
the restoration of some dietary intake.  Alongside this, all patients experienced 
a PVG related challenge/challenges, although the nature and degree of these 
varied.  Ultimately, all patients were pleased they had gone ahead with the 
procedure.  Through the enhancement of information provision and HCPs’ 
education and training, the challenges faced by patients could be mitigated 
somewhat, whilst also acknowledging that it is not always possible to predict 
or prevent side effects and/or complications of a procedure. 
Whilst this study was performed primarily for service evaluation, it is 
important in contributing to the existing published literature, as it is the first 
 in-depth exploration of patients’ experiences of PVG using qualitative 
methods.  Existing literature demonstrates the role of PVG in MBO in terms of 
technical success rates, complications, effectiveness of symptomatic control 
and survival.  This study can be used to improve awareness of PVG and the 
understanding of how PVG insertion can affect patients.  In addition, the use of 
mixed methods (qualitative interviews combined with reviews of patients’ 
medical notes) enabled a greater depth to the data analysis. 
Patient selection for PVG is an important area to consider.  The results suggest 
that the medical management of MBO was not always fully optimised pre-PVG.  
Three patients did not have a continuous subcutaneous infusion (CSCI) of 
medication during their current episode of MBO.  This includes Patient 3 whom 
developed skin necrosis, secondary to his tube bypassing.  Ensuring patients 
have undergone a trial of optimal tolerated medical management prior to PVG 
consideration would help to prevent patients unnecessarily undergoing PVG 
insertion.  Defining what this should include is challenging, especially regarding 
choices of medication, drug combinations and doses.  However, amongst the 
patients with a CSCI in situ many of the doses were lower than would usually 
be tried by the Hospital’s Supportive Care/Specialist Palliative Care Team.   
Another factor to consider in patient selection is prognosis.  Patient 3 had the 
shortest post-PVG survival at 10 days.  Estimating prognosis can be difficult and 
inaccurate, but with hindsight at least, this case highlights the need for an 
appropriate clinician to attempt to estimate prognosis when referring patients 
for a PVG. 
In terms of patient selection, this study raises the possibility of creating a 
standardised referral pathway.  Standardised referral pathways are utilised in 
many areas of clinical medicine, however establishing such a pathway in this 
subgroup of patients is more challenging.  Criteria may include: where 
optimally tolerated doses of medications via a parenteral route have failed to 
adequately control symptoms and where a trial of an NGT has been 
symptomatically beneficial.  Ensuring that the patient has been reviewed by 
the Hospital’s Supportive Care/Specialist Palliative Care Team and/or had their 
case discussed at an appropriate MDT meeting will increase the likelihood of 
satisfying the suggested criteria.  
Some of the reported challenges could have been pre-empted or were known 
potential side effects and/or complications of the procedure, such as, patients 
with reduced manual dexterity struggling with tube fastenings and an inverse 
 relationship between the number of attachments and the effect on mobility.  
Known possible side effects and/or complications include infections and 
bypassing tubes causing a leakage of gastric contents.  This reinforces a 
recommendation for individual patient assessment pre-PVG, including an 
explanation of possible side effects and complications, supported by written 
information.  This may help patients to make a more informed decision and 
could reduce some of the challenges, due to patients having more realistic 
expectations. 
Furthermore, complications could be reduced and perhaps avoided through 
training combined with a competency assessment, in the aftercare of PVGs for 
nursing staff.  One example of this is the frequency of tube displacement.  
Patient 6’s comment implies that some nurses might be rotating PVG tubes.  
This may highlight an area of training which needs to be addressed; to ensure 
that staff are aware of the differences between a Percutaneous Endoscopic 
Gastrostomy (PEG) for Clinically Assisted Nutrition (CAN) and PVG.  
Emphasising that despite the equipment being very similar, their management 
is different.  
There is a need to improve the provision of patient information, and this could 
be implemented in several ways: 
• Ensuring that all patients are offered written information.  
• Agreeing a time point, pre-PVG for this information to be provided, 
facilitating adequate reading and processing time, and an opportunity 
to ask questions. 
• Reformatting the written information; separating pre-PVG and post-
PVG; supporting a more flexible and individualised approach to the 
provision of information. 
• Guaranteeing that information is easily accessible to any referring team 
(via the hospital’s intranet); potentially informing, empowering and 
improving both initial pre-PVG as well as post-PVG discussions. 
The above should create a more robust process of informed consent and more 
realistic patient expectations.  
The results demonstrate a complex interplay of individual patient factors 
which shaped these patients’ experiences.  They highlight a need for the 
development of PVG referral criteria to improve patient selection.  In addition, 
 services need to address patient information provision, skills and 
competencies of HCPs and PVG aftercare. 
It is important to acknowledge limitations of the study.  With regards to study 
design, the study period was predetermined to coincide with the study periods 
of the interviewers.  Despite this, the interviewer felt that the saturation point 
had been reached in this period, as no new themes emerged during the last 
two interviews.  There was variation in the time between PVG insertion and 
interview; our aim to interview patients one-week post PVG insertion proved 
challenging.  This was due to interviewer availability and patient factors.  
Interviewing patients only a few days post-PVG meant some were unable to 
provide fully informed views; where this was the case the interviewer 
attempted to organise a re-interview (one of the two re-interviews was 
cancelled as the patient died).  There was a risk of bias in that the interviewers 
were involved in the care of some of the patients; we aimed to minimise this 
by reassuring patients that the doctor was not acting in their HCP role, 
however this does not completely eradicate the risk of bias.  In order to 
counteract the bias associated with two different interviewers, both received 
training and supervision by a senior qualitative researcher.  With regards to the 
patient sample, it included only one male patient.  Although gender was not 
considered a prime purposive sampling criterion, it may be felt that the patient 
group is not truly representative of the general population.  
There are further factors to be explored in future studies, such as a potential 
correlation between the use of parenteral nutrition and survival.  Considering 
the health economics of PVG insertion would also be beneficial, with regards 
to the cost of the insertion procedure compared to a possible reduction in 
acute admission costs.  Furthermore, it would be beneficial to establish if PVG 
enables greater patient autonomy in facilitating factors such as discharge to 
their preferred place of care.  Unfortunately, these considerations were 
beyond the remit of the data collected in this study, but would be useful in 
determining which patients would benefit from PVG in MBO.   
Existing literature demonstrates that PVG is an accepted procedure for the 
symptomatic management of MBO.  This study is the first to focus on patients’ 
experiences of their PVG using qualitative methods, whilst contextualising this 
information with their individual MBO journeys.  We strongly believe that 
despite the limitations of this study, the patient voice conveyed in the results 
 can enhance future care delivery if the suggestions made are implemented as 
per standard quality improvement methodologies. 
 
Table Legends 
TABLE 1: PATIENT CHARACTERISTICS 
TABLE 2: SUMMARY OF PATIENTS' JOURNEYS 
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 Appendix A 
Concurrent Audit Data 
Patient identifying number (NHS/Unit no): ______________ 
Pre-procedure 
• Age______ years 
• Gender 
Male □  Female □ 
• Postcode _________________ 
• Primary diagnosis 
Bowel cancer □     Ovarian cancer □     Other: ______________        
• Date of diagnosis_____________ 
• MBO history 
o Date of MBO 
o Complete or sub-acute 
o Medications 
o Involvement of palliative care team (Y/N) 
• Expected date of death/date of death __________ 
 
PVG 
• Who referred the patient for PVG? 
Palliative Care □     Dietician □      Oncologist □        Surgeon □     Other: 
__________ 
• Date of PVG _____________ 
• Name of practitioner that inserted 
PVG__________________________________ 
• Gastro or gastrojejunostomy 
Gastrostomy □      Gastrojejunostomy □ 
 
• Eastern Co-operative Oncology Group (ECOG) Performance Status Score  
o Pre-procedure:  _________ 
o Post-procedure: _________ 
 
 
 Appendix B 
Semi-structured interview guide 
 
1 Initial symptoms 
1.1 Vomiting 
1.2 Nausea 
1.3 Pain 
1.4 Bloating 
1.5 Bowels 
1.6 Eating and drinking 
2 NGT 
2.1 Reason for insertion 
2.2 Experience of insertion procedure 
2.3 Benefits provided by NGT  
2.4 Negative impact of NGT 
3 PVG: Pre-procedure 
3.1 Reason for insertion 
3.2 Patient expectations of PVG 
3.3 Information provided  
4 PVG: Procedure 
4.1 Sedation and experience 
4.2 Staff 
4.3 Recovery 
5 PVG: Post-procedure 
5.1 Benefits 
5.2 Complications/side-effects 
5.3 Practicalities for the patient  
 5.4 Ongoing care of the PVG 
6 Overall experience of PVG 
6.1 Did a PVG meet their expectations? 
6.2 Does the patient regret the procedure? 
6.3 Would the patient recommend the procedure to another patient?  
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